GlassScriptPhysician profile
Meryl A Perez
NPI 1962729251
$2,446.11
in general payments reported to CMS, 2019-2025
27 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $397 · 2021: $321 · 2022: $237 · 2023: $435 · 2024: $350 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034 · Education: $44.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.75 |
| Education | $44.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $695.80 | 2019-2025 | Ambisome, Cresemba |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.66 | 2019-2023 | Stiolto Respimat, Ofev |
| Glaxosmithkline, LLC. | $239.41 | 2019-2024 | Trelegy Ellipta |
| Gilead Sciences, INC. | $239.14 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $187.53 | 2019-2025 | Fasenra, Airsupra |
| Merck Sharp & Dohme LLC | $104.15 | 2020-2025 | Dificid, Winrevair, Pifeltro |
| Allergan, INC. | $69.91 | 2019-2020 | |
| United Therapeutics Corporation | $56.62 | 2019-2025 | Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $54.18 | 2020-2023 | Glassia |
| Actelion Pharmaceuticals US, INC. | $53.30 | 2021-2023 | Opsumit, Uptravi |
| Abbvie INC. | $50.82 | 2022-2023 | Teflaro |
| Advanced Respiratory, INC | $45.34 | 2020 | |
| Paratek Pharmaceuticals, INC. | $43.33 | 2021-2022 | |
| Philips North America LLC | $42.98 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $38.48 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $33.40 | 2021-2023 | Symtuza |
| Viiv Healthcare Company | $30.76 | 2023 | Cabenuva |
| Vyera Pharmaceuticals, LLC | $22.62 | 2019 | |
| Alexion Pharmaceuticals, INC. | $21.69 | 2022 | |
| Horizon Therapeutics Plc | $20.84 | 2020 | |
| Pfizer INC. | $20.70 | 2020 | |
| Grifols USA, LLC | $18.59 | 2020 | |
| Optinose US, INC. | $18.34 | 2020 | |
| Baxter Healthcare | $15.72 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Electromed, INC. | $15.34 | 2023 | Smartvest |
| Mylan Specialty L.P. | $15.05 | 2024 | Yupelri |
| Emd Serono, INC. | $14.41 | 2023 | Serostim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meryl Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.